Rubarox 10/15/20 10 mg, 15 mg, 20 mg Tablets
PDF Leaflet Revision Date: 18 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of VTE, stroke, and treatment of DVT/PE.
Dosage (summary)
VTE: 10 mg once daily; SPAF: 20 mg once daily; DVT/PE: 15 mg twice daily for 3 weeks, then 20 mg once daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Strong CYP 3A4 inhibitors
- Warfarin
- NSAIDs
Contraindications
- Active bleeding
- Hepatic disease with coagulopathy
- Hypersensitivity to rivaroxaban
Common side effects
- Bleeding
- Anaemia
- Dizziness
Counselling Points
- Take with food.
- Monitor for signs of bleeding.
- Do not double doses.
Serious warnings
- Increased bleeding risk in certain populations
- Caution with neuraxial anesthesia
Important Disclaimer
The Rubarox 10/15/20 10 mg, 15 mg, 20 mg Tablets professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
